SEQUAR SEmitendinosus vs QUadriceps in Anterior Cruciate Ligament Reconstruction
Launched by KAROLINSKA INSTITUTET · Mar 2, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called SEQUAR, is comparing two different types of grafts used in surgery to repair the Anterior Cruciate Ligament (ACL), which is a key ligament in the knee that can be injured during sports or physical activities. The two grafts being studied are taken from the semitendinosus muscle (located in the back of the thigh) and the quadriceps muscle (located in the front of the thigh). The goal is to see which graft works better for patients who need ACL reconstruction.
To be eligible for this trial, participants should be between the ages of 18 and 40 and have a Tegner score of 7 or higher before their injury, which indicates they were very active in sports. Certain individuals, like those who have had multiple knee injuries or previous knee surgeries, may not qualify. If you join the study, you’ll receive one of the two grafts during your ACL surgery, and your recovery will be closely monitored. This trial is taking place at the Capio Artro Clinic in Stockholm, where the doctors have a lot of experience with these types of surgeries. If you're considering participating, it could help improve ACL repair techniques for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pre-injury Tegner Activity Scale≥7
- • Intended return to sports to prior sport and Tegner Activity Scale Level
- • Time between injury and inclusion not more than 6 months
- • MR verified ACL rupture
- Exclusion Criteria:
- • Previous knee injury with symptoms before ACL injury
- • Neurological disease, inflammatory disease, connective tissue disease or balance disorder
- • Previous lower limb fracture or surgery
- • Laxity in the medial collateral ligament (MCL) and lateral collateral ligament (LCL) \> grade 1
- • PCL rupture or Multiligament knee injury (MLKI)
- • Radiographic sign of osteoarthritis (OA)
- • Previous knee surgery or ligament injury in contralateral knee
- • Beighton score ≥ 5
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
Anders Stålman, MD,PhD
Principal Investigator
Karolinska Institutet
Mikael Östin, MD
Principal Investigator
Capio Artro Clinic AB
Vasileios Sarakatsianos, MD
Principal Investigator
Karolinska Institutet
Joanna Kvist, PhD
Principal Investigator
Karolinska Institutet
Daniel Castellanos, MD
Principal Investigator
Karolinska Institutet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials